

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
24 January 2008 (24.01.2008)

PCT

(10) International Publication Number
WO 2008/010765 A1

(51) International Patent Classification:

C07D 491/107 (2006.01) C07C 235/60 (2006.01)
A61K 31/438 (2006.01) C07D 211/48 (2006.01)
A61P 11/00 (2006.01) C07D 303/23 (2006.01)

(21) International Application Number:

PCT/SE2007/000694

(22) International Filing Date: 17 July 2007 (17.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/831,776 19 July 2006 (19.07.2006) US

(71) Applicant (for all designated States except US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ELKINS, Barry** [US/US]; SAFC Pharma, 3050 Spruce Street, St. Louis, Missouri 63103 (US). **ENNIS, David** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **ERIKSSON, Tomas** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **GIBSON, Scott** [US/US]; SAFC Pharma, 3050 Spruce Street, St. Louis, Missouri 63103 (US). **GU, Eric** [CN/CN]; Wuxi Pharma Tech Co. Ltd, No. 1 Building #288, Fu Te ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131 (CN). **HASSALL, Ian** [US/US]; SAFC Pharma, 3050 Spruce Street, St. Louis, Missouri 63103 (US). **HEMMERLING, Martin** [DE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **JOSEFSSON, Bo-Göran** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **IVANOVA, Svetlana** [RU/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **KAVITAKE, Santosh** [IN/IN]; AstraZeneca India Pvt Ltd, Bellary Road, Hebbal,


Bangalore 560 024 (IN). **KUMAR, Sythana, Suresh** [IN/IN]; AstraZeneca India Pvt Ltd, Bellary Road, Hebbal, Bangalore 560 024 (IN). **KUMAR, Vinod** [IN/IN]; AstraZeneca India Pvt Ltd, Bellary Road, Hebbal, Bangalore 560 024 (IN). **LINGESHA, Sidda** [IN/IN]; AstraZeneca India Pvt Ltd, Bellary Road, Hebbal, Bangalore 560 024 (IN). **MENSONIDES-HARSEMA, Marguérite** [NL/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **MERIFIELD, Eric** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **MO, John** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **PAVEY, John** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **PIMM, Austen** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **REUBERSON, James** [GB/GB]; AstraZeneca R & D Charnwood, Bakewell Road, Loughborough Leicestershire LE11 5RH (GB). **ROGERS, Mike** [US/US]; SAFC Pharma, 3050 Spruce Street, St. Louis, Missouri 63103 (US). **SCHULZ, Håkan** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **STRANDBERG, Per** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **ZHENG YU, Wang** [CN/CN]; Wuxi Pharma Tech Co. Ltd, No. 1 Building #288, Fu Te ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131 (CN).

(74) Agent: **ASTRAZENECA AB**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,

[Continued on next page]

(54) Title: NOVEL TRICYCLIC SPIROPIPERIDINE COMPOUNDS, THEIR SYNTHESIS AND THEIR USES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY



(I)

(57) Abstract: Compounds of formula (I) wherein R^1 , R^3 , R^4 , R^5 , R^6 , R^7 , and R^{10} are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates useful in the preparation thereof. Beside, the invention relates to salts and polymorphic forms of the new compounds as well as the preparation thereof.



WO 2008/010765 A1



RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.